BMC Cancer

Table 2 CBMNcyt assay results and the effect of gender on the MN and NPB yields

From: Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer

	Women
	MN/BNL			NPB/BNL
	min	max	median	min	max	median
Before RCT (0Gy)	0.005	0.057	0.018	0.000	0.018	0.002
3Gy in vitro	0.032	0.498	0.251	0.001	0.093	0.029
During RCT (21.6Gy)	0.035	0.295	0.140	0.002	0.064	0.018
End RCT (50.4Gy)	0.089	0.593	0.232	0.006	0.241	0.027
1 year after RCT	0.018	0.184	0.081	0.005	0.025	0.008
2 years after RCT	0.012	0.099	0.040	0.002	0.042	0.005
	Men
	MN/BNL			NPB/BNL
	min	max	median	min	max	median
Before RCT (0Gy)	0	0.03	0.012	0	0.027	0.002
3Gy in vitro	0.069	0.899	0.236	0.008	0.211	0.027
During RCT (21.6Gy)	0.047	0.231	0.119	0.003	0.084	0.017
End RCT (50.4Gy)	0.079	0.541	0.219	0.004	0.079	0.022
1 year after RCT	0.018	0.203	0.060	0.003	0.016	0.006
2 years after RCT	0.014	0.067	0.029	0.001	0.021	0.007

RCT radiochemotherapy, MN micronuclei, BNL binuclear lymphocytes, NPB nucleoplasmatic bridges

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com